Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking method to diabetes management. These innovative therapies operate by mimicking the natural actions of GLP-1, a hormone released by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these agents enhance insulin release and inhibit glucagon re

The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting considerable weight decrease – they exhibit intriguing contrasts in